Calcium folinatc CAS 6035-45-6

Introduction：Basic information about Calcium folinatc CAS 6035-45-6, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Calcium folinatc Basic information

• Product Name: Calcium folinatc
• Synonyms: calcium 2-[[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]phenyl]-oxomethyl]amino]pentanedioate pentahydrate;FOLINIC ACID CALCIUM CELL CULTURE TESTED;Folinic acid, calcium salt pentahydrate, 95.0-105.0%;Calcium folinatc;Folinic acid calcium salt;Leucovorin calcium pentahydrate;NSC-3590;CALCIUM FOLINATE(FOLINIC ACID)(RG)
• CAS: 6035-45-6
• MF: C20H27CaN7O8
• MW: 533.56
• Product Categories: API;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Calcium, Calcium Folinatc, Citrovorum Factor;Miscellaneous Biochemicals
• Mol File: 6035-45-6.mol

Calcium folinatc Chemical Properties

• Melting point: 240-250°C
• alpha: D21 +14.9° (c = 1 in water)
• storage temp.: Keep in dark place,Inert atmosphere,2-8°C
• solubility: insoluble in DMSO; insoluble in EtOH; ≥15.04 mg/mL in H2O with gentle warming
• form: powder
• color: Yellow-white to yellow
• InChIKey: QUCDGUZWVVGQDO-WJYQJPTCNA-N
• SMILES: C(N1C(CNC2NC(N)=NC(=O)C1=2)CNC1C=CC(C(=O)N[C@H](C(=O)O)CCC(=O)O)=CC=1)=O.[Ca].O |&1:22,r|

Safety Information

• Hazard Codes: Xn
• Risk Statements: 36/37/38-42/43
• Safety Statements: 26-36
• WGK Germany: 3
• HS Code: 29362900

Calcium folinatc Usage And Synthesis

Chemical Properties

yellowish-white to yellow powder

Uses

An intermediate product of the metabolism of Folic Acid. This compound is a mixture of diastereomers.

Uses

Antianemic

Brand name

Wellcovorin (GlaxoSmithKline).

Biological Activity

human lymphoid cell lines were studied for leucovorin requirements to protect from methotrexate (mtx)-induced growth suppression. over a 72h continuous exposure leucovorin provided better protection to the cell lines laz-007 and raji than to the cell line

in vivo

Folinic acid (7.0 mg/kg; intraperitoneal injection; every second day; for 3 weeks; Balb/c young growing male mice) treatment following methotrexate (MTX) administration appears to reverse this growth inhibition (Chronic administration of MTX induces suppression of skeletal growth in mice)^[2].

• Animal Model: 24 Balb/c young growing male mice aged 3 weeks (11.88 ± 0.25 g)^[2]
• Dosage: 7.0 mg/kg
• Administration: Intraperitoneal injection; every second day; for 3 weeks
• Result: Following methotrexate (MTX) administration appears to reverse this growth inhibition.

IC 50

Human Endogenous Metabolite